Find Paid Clinical Trials in Montana

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Montana

Top of Directory » All Locations » United States » Montana




  • To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: decitabine;   Drug: azacitidine
    Sponsor:   Eisai Inc.
    Not yet recruiting - verified November 2009

  • Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

    Condition:   Type II Diabetes Mellitus
    Interventions:   Drug: JTT-654;   Drug: JTT-654 Placebo
    Sponsor:   Akros Pharma Inc.
    Recruiting - verified November 2009

  • Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

    Condition:   Gout
    Interventions:   Drug: placebo;   Drug: BCX4208
    Sponsor:   BioCryst Pharmaceuticals
    Recruiting - verified November 2009

  • Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

    Condition:   Influenza Infection
    Interventions:   Biological: GSK2340273A;   Biological: Saline placebo;   Biological: GSK2340274A
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects With Confirmed or Suspected Influenza Infection

    Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Feverishness;   Fatigue
    Interventions:   Drug: Peramivir;   Drug: Peramivir
    Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
    Recruiting - verified November 2009

  • Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

    Condition:   Subjective Tinnitus
    Interventions:   Drug: Neramexane mesylate;   Drug: Placebo
    Sponsor:   Merz Pharmaceuticals GmbH
    Recruiting - verified November 2009

  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009

  • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

    Condition:   Acute Bacterial Skin and Skin Structure Infections
    Interventions:   Drug: NXL103;   Drug: Linezolid
    Sponsor:   Novexel Inc
    Recruiting - verified November 2009

  • Study of Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Advanced Non-Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

    Condition:   Alzheimer's Disease
    Intervention:   Drug: Dimebon
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting - verified November 2009

  • Dinaciclib in Treating Patients With Stage IV Melanoma

    Condition:   Melanoma (Skin)
    Intervention:   Drug: dinaciclib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus BSI-201
    Sponsor:   BiPar Sciences
    Recruiting - verified November 2009

  • A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

    Condition:   Postmenopausal Osteoporosis
    Interventions:   Drug: Ibandronate;   Drug: Denosumab
    Sponsor:   Amgen
    Not yet recruiting - verified November 2009

  • Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

    Condition:   Carcinoma of Unknown Primary
    Interventions:   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: NVA237;   Drug: Placebo to NVA;   Drug: Tiotropium
    Sponsor:   Novartis
    Recruiting - verified November 2009

  • Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections

    Condition:   Complicated Urinary Tract Infection
    Interventions:   Drug: CXA-101;   Drug: Ceftazidime
    Sponsor:   Calixa Therapeutics, Inc.
    Recruiting - verified November 2009

  • Collecting and Storing Samples From Patients With Lung Cancer

    Condition:   Lung Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

    Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous/Nonmalignant Condition
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

    Condition:   Benign Prostatic Hyperplasia
    Interventions:   Drug: NX-1207;   Drug: Placebo
    Sponsor:   Nymox Corporation
    Recruiting - verified October 2009

  • A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: LCQ908A;   Drug: LCQ908A;   Drug: LCQ908A;   Drug: LCQ908A;   Drug: LCQ908A;   Drug: Placebo;   Drug: Sitagliptin
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified October 2009

  • Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

    Condition:   Lymphoma
    Intervention:   Other: cryopreservation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

    Conditions:   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous/Nonmalignant Condition
    Interventions:   Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

    Condition:   Lymphoma
    Interventions:   Other: biologic sample preservation procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
    Interventions:   Drug: capecitabine;   Drug: sunitinib malate
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: Nonbiologic DMARDs of investigator's choice
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: abiraterone acetate plus prednisone/prednisolone;   Drug: placebo plus prednisone/prednisolone
    Sponsor:   Cougar Biotechnology, Inc.
    Recruiting - verified November 2009

  • A Study of Patients With Relapsing Remitting Multiple Sclerosis

    Condition:   Relapsing-Remitting Multiple Sclerosis
    Interventions:   Drug: LY2127399;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Procedure: axillary lymph node dissection;   Procedure: neoadjuvant therapy;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: ultrasound imaging
    Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

    Conditions:   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dexamethasone;   Drug: gabapentin;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: neratinib;   Other: placebo
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

    Condition:   Euvolemic Hyponatremia
    Interventions:   Drug: Lixivaptan;   Drug: Placebo
    Sponsors:   CardioKine Inc.;   Cardiokine Biopharma, LLC;   Biogen Idec
    Recruiting - verified November 2009

  • Thiazolidinedione Intervention With Vitamin D Evaluation

    Conditions:   Cardiovascular Disease;   Type 2 Diabetes Mellitus
    Interventions:   Drug: pioglitazone;   Drug: placebo;   Dietary Supplement: vitamin D;   Dietary Supplement: placebo;   Drug: rosiglitazone
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

    Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Procedure: assessment of therapy complications
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

    Conditions:   Coronary Artery Bypass;   Myocardial Infarction;   Ventricular Dysfunction, Left;   Stroke;   Cardiopulmonary Bypass
    Interventions:   Drug: Acadesine;   Drug: Normal Saline
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

  • Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

    Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
    Intervention:   Drug: zoledronic acid
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

    Condition:   Diseases Caused by Measles, Mumps, Rubella and Varicella Viruses
    Interventions:   Biological: Havrix®;   Biological: Prevnar®;   Biological: M-M-R® II (Merck and Co);   Biological: Varivax®;   Biological: GSK Biological's investigational vaccine 209762
    Sponsor:   GlaxoSmithKline
    Recruiting - verified October 2009

  • Acute Pain Caused by Paclitaxel in Patients With Cancer

    Conditions:   Chemotherapeutic Agent Toxicity;   Neurotoxicity;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: paclitaxel;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: assessment of therapy complications
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cytarabine;   Drug: idarubicin;   Drug: pravastatin
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes.

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: metformin + glimepiride + pioglitazone placebo + albiglutide placebo;   Drug: metformin + glimepiride + pioglitazone + albiglutide placebo;   Biological: metformin + glimepiride + pioglitazone placebo + albiglutide
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: glimepiride;   Drug: metformin;   Drug: sitagliptin;   Biological: albiglutide
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials